Inhibition by heparin and derivatized dextrans of Staphylococcus epidermidis adhesion to in vitro fibronectin-coated or explanted polymer surfaces.
The ability of Staphylococcus aureus to recognize several extracellular matrix or plasma proteins (e.g., fibrinogen, fibronectin, and collagen) promotes bacterial attachment to artificial surfaces. Whereas most S. aureus clinical isolates elaborate a wide repertoire of bacterial surface receptors' called adhesins, exhibiting specific binding of individual host proteins, S. epidermidis is lacking most of such protein adhesins. To document the interactions between S. epidermidis and various surface-adsorbed proteins, we first compared promotion of bacterial attachment by seven purified human proteins immobilized onto poly(methyl methacrylate) (PMMA) coverslips. Only two of them, namely fibronectin and fibrinogen, exhibited adhesion-promoting activities. In the presence of native heparin or two functionalized dextrans (CMDBS for Carboxy Methyl, Benzylamide sulfonate/sulfate), a dose-dependent inhibition of S. epidermidis adhesion to fibronectin-coated, but not to fibrinogen-coated surfaces was observed. The inhibitory effects of each CMDBS were much stronger than that of native heparin. In contrast, a control highly negatively charged, dextran exclusively substituted with carboxy methyl groups exerted no inhibition on S. epidermidis adhesion. To evaluate how CMDBS could interfere with S. epidermidis attachment to coverslips coated in vivo with extracellular matrix components, we also tested PMMA surfaces retrieved from tissue cages subcutaneously implanted in guinea pigs. Each CMDBS, but not heparin, strongly inhibited S. epidermidis adhesion to explanted coverslips, even in the presence of tissue cage fluid. In conclusion, fibronectin plays an important role in promoting S. epidermidis attachment to implanted biomaterials. Furthermore, S. epidermidis adhesion to fibronectin-coated or implanted biomaterials can be efficiently blocked in vitro by CMDBS.
Francois
P
P
Department of Medicine, University Hospital, Geneva, Switzerland. patrice.francois@hcuge.ch
Letourneur
D
D
Lew
D P
DP
Jozefonwicz
J
J
Vaudaux
P
P
D000818:Animals; D001672:Biocompatible Materials; D002448:Cell Adhesion / Q000187:drug effects*; D003169:Complement Inactivator Proteins / Q000494:pharmacology; D003911:Dextrans / Q000494:pharmacology*; D015194:Diffusion Chambers, Culture; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism*; D006168:Guinea Pigs; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D011108:Polymers / Q000378:metabolism*; D019736:Prostheses and Implants; D013212:Staphylococcus epidermidis / Q000166:cytology / Q000378:metabolism*; D013499:Surface Properties
D001672:Biocompatible Materials; D003169:Complement Inactivator Proteins; D003911:Dextrans; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D011108:Polymers; C099253:CMDBS 25; D005340:Fibrinogen; D006493:Heparin